Source: Fox News
Summary
A recent study found that older adults with type 2 diabetes who started taking GLP-1 medications, such as Ozempic and Wegovy, had an 11% higher risk of fragility fractures compared to those taking other diabetes medications. The study, published in the Journal of Clinical Endocrinology & Metabolism, followed over 46,000 adults 65 and older for nearly three years. Researchers suggested that bone health should be assessed before starting these medications in older patients.
Our Reading
The advice sounds familiar. GLP-1 medications are being closely examined for their potential impact on bone health, particularly in older adults. The study’s findings, while observational, raise concerns about the risk of fragility fractures and osteoporosis. The potential mechanisms at play include rapid weight loss, reduced mechanical load on the skeleton, and lower intake of nutrients critical for bone strength. Despite these concerns, experts emphasize that the benefits of GLP-1 medications for blood sugar control, weight loss, and cardiovascular risk reduction should not be overlooked.
The recommendation enters another phase. As research continues to uncover potential risks associated with GLP-1 medications, healthcare providers must weigh these findings against the established benefits of these drugs. It’s essential to consider the complex interplay between weight loss, nutrition, and bone health when prescribing these medications, particularly for older adults.
The guidance has been heard before. The importance of monitoring bone health in patients taking GLP-1 medications is not a new concern. However, the latest research serves as a reminder to prioritize bone density screening and ensure adequate nutrition and resistance training to help preserve muscle and bone during weight loss.
Author: Evan Null
